|
| Status |
Public on Jun 04, 2013 |
| Title |
CD45+ blood cells EV rep1 |
| Sample type |
RNA |
| |
|
| Source name |
CD45+ blood cells EV rep1
|
| Organism |
Homo sapiens |
| Characteristics |
cell type: CD45+ blood cells
genotype/variation: EV
precursor: No
|
| Extracted molecule |
total RNA |
| Extraction protocol |
Hemogenic progenitors (CD31+CD45-) and blood cells (CD45+) derived from hESCs were sorted out at day 15 of EB development for gene expression profiling14,33. The following transgenic hESC lines were used: EV, FLT3-TKD, MLLAF4/FLT3-TKD and MLLAF4/FLT3-WT. Cells were collected and stabilized in Prep-Protec solution (Miltenyi Biotech) until RNA extraction. RNA was isolated using the NucleoSpin RNAII kit, and its quality checked in the Agilent 2100 Bioanalyzer platform (Agilent Technologies). For the linear T7-based amplification, 100ng of each total RNA sample was used
|
| Label |
biotin
|
| Label protocol |
Labeled samples were hybridized overnight with the Gene Expression Hybridization kit to a Whole Human Genome Microarray (G4112F 45.000 probes corresponding to 32.600 genes Agilent Technologies) following the Manufacturer's instructions
|
| |
|
| Hybridization protocol |
Standard Agilent hybridization protocol
|
| Scan protocol |
Standard Agilent scanning protocol
|
| Description |
replicate 1
|
| Data processing |
Primary data was processed with GeneSpring 11.0 software (Silicon Genetics, Redwood City, CA). Data postprocessing was performed with in-house developed functions in Matlab
|
| |
|
| Submission date |
Aug 14, 2012 |
| Last update date |
Jan 15, 2022 |
| Contact name |
Marcos J. Araúzo-Bravo |
| E-mail(s) |
mararabra@yahoo.co.uk
|
| Phone |
+34 943 00 6108
|
| Organization name |
Max Planck Institute for Molecular Biomedicine
|
| Department |
Cell and Developmental Biology
|
| Lab |
Computational Biology and Bionformatics
|
| Street address |
Rogentstrasse
|
| City |
Muenster |
| ZIP/Postal code |
48149 |
| Country |
Germany |
| |
|
| Platform ID |
GPL13607 |
| Series (1) |
| GSE40103 |
FLT3 activation cooperates with MLL-AF4 fusion gene to abrogate the hematopoietic specification of human ESCs |
|
